Today it was reported that the CEO of AxoGen (NASDAQ: AXGN), Karen Zaderej, exercised options to buy 175,000 AXGN shares at $2.74 a share, for a total transaction value of $479.5K.
Following this transaction Karen Zaderej’s holding in the company was increased by 72.01% to a total of $16.07 million. Following Karen Zaderej’s last AXGN Buy transaction on October 14, 2016, the stock climbed by 29.7%.
See today’s analyst top recommended stocks >>
Based on AxoGen’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $20.58 million and GAAP net loss of $7.43 million. In comparison, last year the company earned revenue of $15.17 million and had a GAAP net loss of $2.06 million. Currently, AxoGen has an average volume of 507.2K. The Company has a Price to Book ratio of 9.9403.
Starting in November 2016, AXGN received 23 Buy ratings in a row. Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $53.33, reflecting a -26.8% downside. Seven different firms, including Merrill Lynch and Cantor Fitzgerald, currently also have a Buy rating on the stock.
The insider sentiment on AxoGen has been neutral according to 25 insider trades in the past three months. This sentiment is slightly lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provide products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity.
